J Breast Cancer.  2020 Feb;23(1):1-9. 10.4048/jbc.2020.23.e17.

Matrix Metallopeptidase 3 Polymorphisms: Emerging genetic Markers in Human Breast Cancer Metastasis

• Suhaimi SA
• Chan SC
• Rosli R

• KMID: 2470877
• DOI: http://doi.org/10.4048/jbc.2020.23.e17

Abstract

Matrix metallopeptidase 3 or MMP3, is a zinc-dependent proteolytic enzyme that is involved in various physiological processes via modification of the extracellular matrix. In particular, its over-expression has been associated with cancer metastasis and tumor growth in various cancers including breast cancer. MMP3 gene expression is regulated by several factors such as DNA polymorphisms which also serve as risk factors for breast cancer. As such, DNA polymorphisms of MMP3 have the potential to be utilized as genetic biomarkers for prediction and prognosis of metastatic breast cancer. Presently, genome-wide association studies of MMP3 gene polymorphisms which are associated with breast cancer risk and patient survival in a variety of populations are reviewed. In order to understand the potential role of MMP3 polymorphisms as genetic markers for breast cancer metastasis, the domain structure of MMP3, the regulation of its expression and its role in breast cancer metastasis are also briefly discussed in this review. The emergence of MMP3 gene polymorphisms as prognostic biomarker candidates for breast cancer metastasis may contribute towards improving targeted therapies and categorization of breast cancer cases in order to provide a better and more accurate prognosis.

Keyword

Breast; Carcinoma; Neoplasm metastasis; Matrix metalloproteinase 3

MeSH Terms

Biomarkers
Breast Neoplasms*
Breast*
DNA
Extracellular Matrix
Gene Expression
Genetic Markers*
Genome-Wide Association Study
Humans*
Matrix Metalloproteinase 3
Neoplasm Metastasis*
Physiological Processes
Prognosis
Risk Factors
Biomarkers
DNA
Genetic Markers
Matrix Metalloproteinase 3

Figure

• 

  Figure 1 The domain structure of MMP3 (adapted from Visse and Nagase, 2003). The domain organization of MMP3 includes S, Pro, Cat, Hpx. MMP3 = matrix metallopeptidase 3; S = translocation signal peptide; Pro = propeptide; Cat = catalytic domain; Hpx = hemopexin domain.

• 

  Figure 2 Schematic representatives of MMP3 gene with localisation of single nucleotide polymorphisms [43]. MMP3 = matrix metallopeptidase 3; mRNA = messenger RNA.

Reference

1. Slattery ML, John E, Torres-Mejia G, Stern M, Lundgreen A, Hines L, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013; 8:e63165.

2. Chaudhary AK, Nadkarni AH, Pandya S, Ghosh K. Matrix metalloproteinase and its inhibitors in cancer progression. In : Dhalla NS, Chakraborti S, editors. Role of Proteases in Cellular Dysfunction. New York (NY): Springer;2014. p. 147–158.

3. Ting WC, Chen LM, Pao JB, Yang YP, You BJ, Chang TY, et al. Genetic polymorphisms of matrix metalloproteinases and clinical outcomes in colorectal cancer patients. Int J Med Sci. 2013; 10:1022–1027.

4. Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000; 2:252–257.

5. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002; 52:255–264.

6. Yang X, Hu JW, Qiu MT, Li M, Yin R, Wang J, et al. Association of matrix metalloproteinase-3 -1171(5A>6A) polymorphism with cancer risk: a meta-analysis of 41 studies. PLoS One. 2014; 9:e87562.

7. Decock J, Thirkettle S, Wagstaff L, Edwards DR. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med. 2011; 15:1254–1265.

8. Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ. Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol. 1997; 139:1861–1872.

9. Munhoz FB, Godoy-Santos AL, Santos MC. MMP-3 polymorphism: genetic marker in pathological processes (review). Mol Med Rep. 2010; 3:735–740.

10. Sternlicht MD, Lochter A, Sympson CJ, Huey B, Rougier JP, Gray JW, et al. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell. 1999; 98:137–146.

11. Hadler-Olsen E, Winberg JO, Uhlin-Hansen L. Matrix metalloproteinases in cancer: their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 2013; 34:2041–2051.

12. Sipos F, Germann TM, Wichmann B, Galamb O, Spisák S, Krenács T, et al. MMP3 and CXCL1 are potent stromal protein markers of dysplasia-carcinoma transition in sporadic colorectal cancer. Eur J Cancer Prev. 2014; 23:336–343.

13. Hassan SA, Hammam O, Htwe TT, Ghanem HZ. Possible diagnostic/prognostic role of survivin and MMP3 in breast cancer disease. J Multidiscip Eng Sci Technol. 2015; 2:3121–3127.

14. Lei H, Hemminki K, Altieri A, Johansson R, Enquist K, Hallmans G, et al. Promoter polymorphisms in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat. 2007; 103:61–69.

15. Liu D, Guo H, Li Y, Xu X, Yang K, Bai Y. Association between polymorphisms in the promoter regions of matrix metalloproteinases (MMPs) and risk of cancer metastasis: a meta-analysis. PLoS One. 2012; 7:e31251.

16. Lynch CC, Matrisian LM. Matrix metalloproteinases in tumor-host cell communication. Differentiation. 2002; 70:561–573.

17. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006; 69:562–573.

18. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999; 274:21491–21494.

19. Koujan SE, Gargarib BP, Khalili M. Matrix metalloproteinases and breast cancer. Thrita. 2015; 4:e21959.

20. Jobin PG, Butler GS, Overall CM. New intracellular activities of matrix metalloproteinases shine in the moonlight. Biochim Biophys Acta Mol Cell Res. 2017; 1864:2043–2055.

21. AbdRaboh NR, Bayoumi FA. Gene polymorphism of matrix metalloproteinases 3 and 9 in breast cancer. Gene Rep. 2016; 5:151–156.

22. Mehner C, Miller E, Nassar A, Bamlet WR, Radisky ES, Radisky DC. Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer. 2015; 6:480–489.

23. Banik D, Netherby CS, Bogner PN, Abrams SI. MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction. Oncotarget. 2015; 6:15164–15179.

24. Yan C, Boyd DD. Regulation of matrix metalloproteinase gene expression. J Cell Physiol. 2007; 211:19–26.

25. Weber GF. Molecular mechanisms of cancer. Dordrecht: Springer Netherlands;2007.

26. Krishnaveni D, Bhayal AC, Shravan KP, Jyothy A, Pratibha N, Venkateshwari A. Heterozygosity of stromelysin-1 (rs3025058) promoter polymorphism is associated with gastric cancer. Indian J Cancer. 2015; 52:251–254.

27. Xiangpo P, Shuzhen L, Jianfeng G, Haiyu L, Haipeng R, Hunanxin W, et al. Current evidence on the association between four polymorphisms in the matrix metalloproteinases (MMP) gene and breast cancer metastasis. J Environ Anal Chem. 2015; 2:151.

28. Srivastava P, Kapoor R, Mittal RD. Impact of MMP-3 and TIMP-3 gene polymorphisms on prostate cancer susceptibility in North Indian cohort. Gene. 2013; 530:273–277.

29. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996; 271:13055–13060.

30. Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, et al. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002; 8:3820–3823.

31. Holliday DL, Hughes S, Shaw JA, Walker RA, Jones JL. Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion. Breast Cancer Res. 2007; 9:R67.

32. Motevalibashi M, Hojati Z, Haji Hosseini S. The function of SNP at -1171 MMP-3 promoters in susceptibility to breast cancer in Isfahan population. Iran J Biol. 2008; 20:399–405.

33. Padala C, Tupurani MA, Puranam K, Gantala S, Shyamala N, Kondapalli MS, et al. Synergistic effect of collagenase-1 (MMP1), stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in breast cancer. PLoS One. 2017; 12:e0184448.

34. Shevchenko AV, Konenkov VI, Garbukov EI, Stakheeva MN. Associating of polymorphism in the promoter regions of genes of metalloproteinase (MMP2, MMP3, MMP9) with options of the clinical course of breast cancer in Russian women. Vopr Onkol. 2014; 60:630–635.

35. Rebbeck TR, Ambrosone CB, Bell DA, Chanock SJ, Hayes RB, Kadlubar FF, et al. SNPs, haplotypes, and cancer: applications in molecular epidemiology. Cancer Epidemiol Biomarkers Prev. 2004; 13:681–687.

36. Lei H, Zaloudik J, Vorechovsky I. Lack of association of the -1171 (5A) allele of the MMP3 promoter with breast cancer. Clin Chem. 2002; 48:798–799.

37. Motovali-Bashi M, Hojati Z, Hajihoseiny S. The role of matrix metalloproteinase-3 functional 5A/6A promoter polymorphism in tumor cell progression and metastasis of breast cancer. Iran J Biotechnol. 2008; 6:45–49.

38. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Köppel H, Leithner A, et al. The 5A/6A polymorphism of the matrix metalloproteinase 3 gene promoter and breast cancer. Clin Cancer Res. 2004; 10:3518–3520.

39. Knechtel G, Hofmann G, Gerger A, Renner W, Langsenlehner T, Szkandera J, et al. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol. 2010; 136:1813–1819.

40. AACR Annual Meeting. Polymorphisms in matrix metalloproteinase genes 1, 3, 9, and 12 and risk of breast cancer: the multiethnic cohort study. San Diego: AACR;2008.

41. Hughes S, Agbaje O, Bowen RL, Holliday DL, Shaw JA, Duffy S, et al. Matrix metalloproteinase single-nucleotide polymorphisms and haplotypes predict breast cancer progression. Clin Cancer Res. 2007; 13:6673–6680.

42. Beeghly-Fadiel A, Cai Q, Lu W, Long J, Gao YT, Shu XO, et al. No association between matrix metalloproteinase-1 or matrix metalloproteinase-3 polymorphisms and breast cancer susceptibility: a report from the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev. 2009; 18:1324–1327.

43. Chan SC. Identification and analysis of single nucleotide polymorphisms in matrix metallopeptidase 2 and 3 genes in Malaysian breast cancer patients [doctor's thesis]. Serdang: Universiti Putra Malaysia;2013.